Skip Navigation
  Print Page

Staff Detail

Skip sharing on social media links
Share this:

Zajicek, Anne

Formal Title:

Chief, OPPB, CRMC

Responsibilities:

The Obstetric and Pediatric Pharmacology and Therapeutics Branch supports research in pediatric and obstetric clinical pharmacology. This encompasses basic, translational, and clinical pharmacology in children and pregnant women,including developmental pharmacology, pharmacogenomics, pharmacoepidemiology, and research related to development of pediatric dosage forms.

Phone:

301-435-6865

Email:

zajiceka@mail.nih.gov

Address:

6100 Executive Blvd Room 4A01, MSC 7510
Bethesda Md 20892-7510
For FedEx use:
Rockville Md 20852

Biosketch:

Anne Zajicek, M.D., Pharm.D., is a board-certified pediatrician and pediatric clinical pharmacologist who currently serves as Chief of the Obstetric and Pediatric Pharmacology and Therapeutics Branch at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). She received a Bachelor’s degree in Pharmacy from Duquesne University and a PharmD from the State University of New York at Buffalo; completed a postdoctoral fellowship in the Department of Pharmaceutics of St. Jude Children’s Research Hospital; and served as an assistant professor at the University of Colorado School of Pharmacy and a Clinical Pharmacist at National Jewish Hospital and Research Center. In 1991, Dr. Zajicek entered medical school at the University of Pittsburgh, and, in 1998, completed a residency in pediatrics at the Children’s Hospital of Pittsburgh. She practiced primary care pediatrics for 2 years and then continued her training as a pediatric clinical pharmacology fellow at Stanford University. She subsequently joined the U.S. Food and Drug Administration (FDA) in the Office of Clinical Pharmacology and Biopharmaceutics. She joined NICHD as a Pediatric Medical Officer in August 2003, and was appointed Chief of the Obstetric and Pediatric Pharmacology and Therapeutics Branch in 2010.  The Branch is responsible for the NIH implementation of the Best Pharmaceuticals for Children Act. The Branch manages a portfolio of grants in obstetric and pediatric pharmacology training and basic, translational and clinical research. 

Publications (PubMed):

 
Title Authors Publication Date
Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.Giacoia GP,Taylor-Zapata P,Zajicek AClin Ther2012 Nov
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.Caritis SN,Sharma S,Venkataramanan R,Hankins GD,Miodovnik M,Hebert MF,Umans JG,Benedetti T,Mattison D,Zajicek A,Fischer D,Jackson A,Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetrical-Fetal Pharmacology Research Units NetworkAm J Obstet Gynecol2012 Nov
Drug studies in newborns: a therapeutic imperative.Giacoia GP,Taylor-Zapata P,Zajicek AClin Perinatol2012 Mar
We don't know what we don't study: the case for research on medication effects in pregnancy.Parisi MA,Spong CY,Zajicek A,Guttmacher AEAm J Med Genet C Semin Med Genet2011 Aug 15
Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.Langholz B,Skolnik JM,Barrett JS,Renbarger J,Seibel NL,Zajicek A,Arndt CAPediatr Blood Cancer2011 Aug
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.Beigi RH,Han K,Venkataramanan R,Hankins GD,Clark S,Hebert MF,Easterling T,Zajicek A,Ren Z,Mattison DR,Caritis SN,Obstetric-Fetal Pharmacology Research Units NetworkAm J Obstet Gynecol2011 Jun
Special challenges in comparative effectiveness research on children's and adolescents' health.Simpson LA,Peterson L,Lannon CM,Murphy SB,Goodman C,Ren Z,Zajicek AHealth Aff (Millwood)2010 Oct
Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.Haas DM,Renbarger JL,Denne S,Ahmed MS,Easterling T,Feibus K,Meslin EM,Koren G,Zajicek A,Snodgrass WR,Flockhart DAClin Transl Sci2009 Feb
The National Institutes of Health and the Best Pharmaceuticals for Children Act.Zajicek APaediatr Drugs2009
Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations.McGrath PJ,Walco GA,Turk DC,Dworkin RH,Brown MT,Davidson K,Eccleston C,Finley GA,Goldschneider K,Haverkos L,Hertz SH,Ljungman G,Palermo T,Rappaport BA,Rhodes T,Schechter N,Scott J,Sethna N,Svensson OK,Stinson J,von Baeyer CL,Walker L,Weisman S,White RE,Zajicek A,Zeltzer L,PedIMMPACTJ Pain2008 Sep
Gaps in knowledge in treating pregnant women.Mattison D,Zajicek AGend Med2006 Sep
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.Johnson JR,Bross P,Cohen M,Rothmann M,Chen G,Zajicek A,Gobburu J,Rahman A,Staten A,Pazdur RClin Cancer Res2003 Jun
Last Updated Date: 11/30/2012
Last Reviewed Date: 11/30/2012
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology